Pyrazinamide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Pyrazinamide}} | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
| Line 11: | Line 11: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[ | '''[[Pyrazinamide description|Description]]''' | ||
'''| [[ | '''| [[Pyrazinamide clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Pyrazinamide microbiology|Microbiology]]''' | ||
'''| [[ | '''| [[Pyrazinamide indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Pyrazinamide contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Pyrazinamide warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Pyrazinamide adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Pyrazinamide overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Pyrazinamide clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[Pyrazinamide dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Pyrazinamide compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | ||
'''| [[ | '''| [[Pyrazinamide directions for use|Directions For Use]]''' | ||
'''| [[ | '''| [[Pyrazinamide how supplied|How Supplied]]''' | ||
'''| [[ | '''| [[Pyrazinamide labels and packages|Labels and Packages]]''' | ||
==Mechanisms of Action== | ==Mechanisms of Action== | ||
Revision as of 06:31, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages